GLP1 – Reta | Triple GLP-1/GIP/Glucagon Receptor Agonist Research Peptide
Price range: $ 189.00 through $ 479.00 - or subscribe
GLP1 – Reta is a 39-amino-acid triple receptor agonist peptide that activates GLP-1, GIP, and glucagon receptors simultaneously, studied for its role in multi-pathway incretin signaling and metabolic receptor interaction research. Supplied as a lyophilized vial for in-vitro laboratory research use only.
Research-grade specs
- Sequence length: 39 amino acids
- Class: Triple GLP-1 / GIP / glucagon agonist
- Half-life: ~6 days
- Pharmaceutical status: Clinical development (TRIUMPH trials)
Studied applications
- Triple-agonist mechanism research (vs single and dual agonists)
- Body-composition and metabolic-rate studies
- Glucagon-receptor signaling research
- Comparative analysis with dual and single receptor agonist research compounds
Quality & trust
- ≥99% HPLC purity, third-party tested
- Mass spectrometry identity confirmation
- LAL endotoxin testing on every batch
- Batch-specific Certificate of Analysis included
- USA same-day shipping (orders before 2pm CT M-F)
Related research: Semaglutide · Tirzepatide · Why researchers switched suppliers
Research literature
Retatrutide has been the subject of 134 peer-reviewed publications indexed in PubMed. Selected recent literature for research reference:
- Lempesis IG et al. (2026). Obesity pharmacotherapy reimagined: The era of multi-receptor agonists and next-generation metabolic modulators, perspectives and controversies. Metabol Open. PMID: 41948476
- Perez-Tilve D et al. (2026). GIPR:GCGR co-agonism restores normal weight in obese rodents. Mol Metab. PMID: 41997446
- Li Q et al. (2026). Multi-omic profiling reveals Retatrutide alleviates adipose tissue fibrosis via metabolic reprogramming and tissue repair. Diabetol Metab Syndr. PMID: 41964043
- Lian J et al. (2026). Targeting the LPI/GPR55 Axis in MAFLD and MASH: Novel Insights, Therapeutic Strategies and Future Directions. Liver Int. PMID: 41823054
- Panou T et al. (2026). Retatrutide in type 2 diabetes mellitus and obesity: an overview. Expert Rev Clin Pharmacol. PMID: 41785010
References are provided for research reference only. Inclusion of literature does not constitute a recommendation, endorsement, or claim for any specific use of LiveWell Peptides products. Products are sold for laboratory and research use only and are not intended for human consumption, injection, topical application, or any other administration to the human body.
| Quantity | Price | Discount |
|---|---|---|
| 3-5 | $ 181.44 | 4% |
| 6-8 | $ 173.88 | 8% |
| 10-15 | $ 168.21 | 11% |
| 16+ | $ 189.00 | $ 0.00 |
Description
GLP‑1 Reta (Retatrutide) is a premium research‑grade peptide available in the USA, offered exclusively for educational and in‑vitro laboratory studies. This peptide is valued by researchers for its purity, consistency, and reliability, making it an excellent option for advanced peptide research.
At LiveWell Peptides, every product is handled with strict quality standards. GLP‑1 Reta is designed for qualified professionals and laboratories who require dependable materials for experimental and scientific purposes. The focus is on supporting responsible research while ensuring high‑grade peptide quality for controlled laboratory environments.
⚠️ Disclaimer: GLP‑1 Reta is intended strictly for laboratory research and in‑vitro use only. It is not a drug, food, cosmetic, or supplement. This product has not been evaluated or approved by the FDA and is not for human or animal use.
A triple receptor agonist peptide targeting GLP-1, GIP, and glucagon pathways, studied for multi-receptor signaling mechanisms and metabolic pathway interactions in controlled laboratory settings.
Reference Link: Click Here
You may also like
5-Amino-1MQ — NNMT Inhibitor | Research Grade
$ 45.99 - or subscribe and save up to 10%
BPC-157 Peptide — Body Protection Compound | Research Grade
$ 85.99 - or subscribe
CJC-1295 ( no DAC) + IPAMORELIN
Price range: $ 85.00 through $ 115.00 - or subscribe
